CoChat

Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy

Necchi, Andrea, Bratslavsky, Gennady, Corona, Robert J., Chung, Jon H., Millis, Sherri Z., Elvin, Julia A., Vergilio, Jo-Anne, Suh, James, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Killian, Jonathan K., Ali, Siraj M., Schrock, Alexa B., Reddy, Prasanth, Miller, Vincent A., Welsh, Allison, Gay, Laurie M., Ross, Jeffrey S. · 2020 · European Urology Focus
Cited by 52

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND Although both seminomatous and nonseminomatous testicular germ cell tumors (TGCTs) have favorable outcomes with chemotherapy, a subset is chemorefractory, and novel therapeutic options are needed. OBJECTIVE To molecularly characterize chemotherapy-refractory TGCTs. DESIGN, SETTING, AND PARTICIPANTS Archival tissues from 107 chemotherapy-treated and relapsed TGCT patients (23 seminomas; 84 nonseminomas) underwent hybrid-capture-based genomic profiling to evaluate four classes of genomic alterations (GAs). Tumor mutational burden (TMB) and microsatellite instability (MSI) were also measured. INTERVENTION Genomic profiling on tumor samples from chemotherapy-refractory TGCTs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Descriptive analyses and differences between seminoma and nonseminoma subgroups were reported. RESULTS AND LIMITATIONS The mean GA/tumor was 2.9 for seminomas and 4.0 for nonseminomas (p=0.04). KRAS alterations (mainly amplifications) were the most common GAs at the single-gene level (47.8% of seminomas and 51.2% of nonseminomas). RAS-RAF pathway (56.5% vs 52.3%) and cell-cycle pathway (52.2% vs 56.0%) were the most common GA classes in seminomas and nonseminomas, respectively. Receptor tyrosine kinase pathway and PI3K pathway GAs were more frequent in seminomas (p=0.02). Median TMB was 1.8 mutations/Mb for seminomas and 2.7 mutations/Mb for nonseminomas (p=0.098), and MSI-high status was found in one nonseminoma only (1.2%). A lack of clinical outcome correlation is a limitation of the present analyses. CONCLUSIONS In chemotherapy-refractory TGCTs, trials with agents targeting the KRAS pathway may be pursued due to the high frequency of KRAS GAs. Overall, the GAs found in refractory seminomas and nonseminomas differ significantly. Considering the frequency of high TMB or MSI-high status, immunotherapy may benefit a small subset of nonseminomas. PATIENT SUMMARY Testicular cancers that are resistant to or relapse after standard chemotherapy may harbor genomic alterations that are potentially druggable, particularly in the clinical trial setting, and genomic profiling can guide clinical research and disclose therapeutic opportunities for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.euf.2018.07.013

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 52

Metadata

Authors
Necchi, A., Bratslavsky, G., Corona, R. J., Chung, J. H., Millis, S. Z., Elvin, J. A., Vergilio, J.-A., Suh, J., Ramkissoon, S., Severson, E., Daniel, S., Killian, J. K., Ali, S. M., Schrock, A. B., Reddy, P., Miller, V. A., Welsh, A., Gay, L. M., & Ross, J. S.
Venue
European Urology Focus
Publisher
Elsevier BV
Published
2020-01
Volume
6
Issue
1
Pages
122-130
ISSN
2405-4569 (ISSN-L)
OpenAlex
W2883118933
Cited by
52
References
8
FWCI
6.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. https://app.cochat.ai/papers/10.1016/j.euf.2018.07.013
The paper
Necchi, A., Bratslavsky, G., Corona, R. J., Chung, J. H., Millis, S. Z., Elvin, J. A., Vergilio, J.-A., Suh, J., Ramkissoon, S., Severson, E., Daniel, S., Killian, J. K., Ali, S. M., Schrock, A. B., Reddy, P., Miller, V. A., Welsh, A., Gay, L. M., & Ross, J. S. (2020). Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. European Urology Focus. https://doi.org/10.1016/j.euf.2018.07.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.